Corpus Intelligence IC Memo — ROOSEVELT GENERAL HOSPITAL 2026-04-27 01:02 UTC
IC Memo — ROOSEVELT GENERAL HOSPITAL
Investment Committee Memorandum | NM | 12 beds | Grade C | EBITDA uplift $2.7M
🛡️ Public data only — no PHI permitted on this instance.
INVESTMENT COMMITTEE MEMORANDUM  ·  CCN 320084

ROOSEVELT GENERAL HOSPITAL

LOCATIONROOSEVELT, NM·BEDS12·AS OFApril 27, 2026
C
INVESTABILITY
EBITDA BridgeData Room

1. Target Overview & Investment Thesis

ROOSEVELT GENERAL HOSPITAL is a 12-bed community hospital in ROOSEVELT, NM with $36.4M in net patient revenue and a -25.1% operating margin. The hospital serves a payer mix of 40.2% Medicare, 0.0% Medicaid, and 59.8% commercial.

Thesis: Turnaround. Our ML models identify $2.7M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -25.1% to -17.8% (+736bps).

Net Revenue HCRIS$36.4M
Current EBITDA COMPUTED$-9.2M
Operating Margin COMPUTED-25.1%
Occupancy HCRIS15.2%
Revenue / Bed COMPUTED$3.0M
Net-to-Gross HCRIS34.5%
Distress Probability MLnan%

2. Market Context & Competitive Position

55
NM Hospitals
-2.7%
State Median Margin
866
Comparable Hospitals

NM has 55 Medicare-certified hospitals with a median operating margin of -2.7%. The target's margin of -25.1% places it below the state median. Among 866 size-comparable peers (6-24 beds), the median margin is -8.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (6-24), prioritizing same-state peers. 866 hospitals in the comp set.

HospitalStateBedsRevenueMargin
ROOSEVELT GENERAL HOSPITAL (Target)NM12$36.4M-25.1%
FRED HUTCHINSON CANCER CENTERWA20$1.17B-50.0%
WENATCHEE VALLEY HOSPITALWA11$277.5M-4.9%
PORTERVILLE DEVELOPMENTAL CENTCA17$193.6M-6.0%
THE SURGICAL HOSPITAL AT SOUTHOH24$166.6M-3.1%
NATIONAL JEWISH HEALTHCO13$150.4M-50.0%
NORTON SOUND REGIONAL HOSPITALAK18$148.7M-28.6%
TEXAS SPINE AND JOINT HOSPITALTX20$147.3M30.3%
NORTH CENTRAL SURGICAL HOSPITATX24$143.6M32.0%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.7M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$765K+210bp18mo
Cost to Collect4.5%2.5%$729K+200bp12mo
Denial Rate Reduction12.0%6.5%$721K+198bp12mo
A/R Days Reduction5200.0%3800.0%$443K+122bp9mo
Clean Claim Rate88.0%96.0%$23K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$765K
Cost to Collect
$729K
Denial Rate Reduction
$721K
A/R Days Reduction
$443K
Clean Claim Rate
$23K
Total EBITDA Uplift$2.7M
Current EBITDA$-9.2M
+ RCM Uplift+$2.7M
Pro Forma EBITDA$-6.5M
Current Margin-25.1%
Pro Forma Margin-17.8%
WC Released (1x)$1.4M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-14.1M$-33.6M0.00x-100.0%
Base (11x exit)10.0x11.0x$-14.1M$-41.5M0.00x-100.0%
Bull Case9.0x11.0x$-12.7M$-37.2M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-12.7M$-44.4M0.00x-100.0%
Bear Case11.0x10.0x$-15.5M$-42.4M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-15.5M$-51.7M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 15.2%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 866 hospitals with 6-24 beds
  • Same-state prioritization (n=9)
  • Comp margins: P25=-22.6% / P50=-8.4% / P75=2.6%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 27, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.